Last updated on: 19/07/2016
1. Contact details{View data sources/studies associated with this centre}
Name of organisation 
1) Department/Research group
2) Organisation/affiliationNetherlands Pharmacovigilance Centre Lareb
Short Name in the inventoryNetherlands Pharmacovigilance Centre Lareb
Website/Homepagewww.lareb.nl 
Administrative Contact
Title Professor
Last name van Puijenbroek
First name Eugene
Address line 1Goudsbloemvallei 7
Address line 2 
Address line 3 
City's-Hertogenbosch 
Postcode5237MH 
CountryNetherlands
Phone number (incl. country code)31-73-6469700 
Alternative phone number 
Fax number (incl. country code)31-73-6426136 
Email address e.vanpuijenbroek@lareb.nl
Scientific Contact
Title Professor
Last name van Puijenbroek
First name Eugene
Address line 1Goudsbloemvallei 7
Address line 2 
Address line 3 
City's-Hertogenbosch 
Postcode5237MH 
CountryNetherlands
Phone number (incl. country code)31-73-6469700 
Alternative phone number 
Fax number (incl. country code)31-73-6426136 
Email address e.vanpuijenbroek@lareb.nl
Alternative Scientific Contact
Title Dr 
Last name Kant 
First name Agnes 
Address line 1Goudsbloemvallei 7 
Address line 2 
Address line 3 
City's-Hertogenbosch 
Postcode5237MH 
CountryNetherlands 
Phone number (incl. country code)31-73-6469700 
Alternative phone number 
Fax number (incl. country code)31-73-6426136 
Email address a.kant@lareb.nl 
2. Description
The Netherlands Pharmacovigilance Centre Lareb collects and analyses reports of suspected adverse drug reactions reported by health care professionals, patients and market authorisation holders in the Netherlands. Lareb informs both government and health professionals about important new signals. The Lareb database presently contains over 100.000 reports. Reports are reviewed on a case-by-case basis. Potential signals undergo further analysis. Statistical techniques are used to support the signal detection process. In addition Lareb gathers information of adverse drug reactions by means of an intensive monitoring system. In his system patients are included when they collect the drug under investigation in the pharmacy for the first time. After on-line registration, the patient will receive questionnaires via e-mail at specific points in time asking for experiences with the drug, including adverse drug reactions (ADRs) and other information related to drug use.
3. Category
Charity or non-profit organisation
4. Available resources
 In houseVia Contacts/Network
Top